Legend Biotech: Why I'm Ready To Go Long Again
Legend Biotech Corp reported higher Q2 sales driven by strong demand for its Carvykti therapy. The company also highlighted promising Phase 1 results for its LB2501 CAR‑T candidate. Based on these developments, the analyst indicated renewed confidence in taking a long position on the stock.
- ▪Q2 sales rose due to increased demand for the Carvykti CAR‑T therapy.
- ▪Carvykti is co‑developed with Johnson & Johnson and is a key revenue driver.
- ▪LB2501, a next‑generation CAR‑T candidate, demonstrated encouraging safety and efficacy signals in Phase 1 trials.
- ▪The analyst believes the pipeline progress justifies a renewed long recommendation on Legend Biotech.
Seeking Alpha files mainly under finance. We currently carry 6,098 of its stories.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Stock Ideas","item":"https://seekingalpha.com/stock-ideas"},{"@type":"ListItem","position":3,"name":"Long Ideas","item":"https://seekingalpha.com/stock-ideas/long-ideas"},{"@type":"ListItem","position":4,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4925266-legend-biotech-why-im-ready-to-go-long-again"},"author":{"@type":"Person","name":"ALLKA…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
